Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells

Cancer Research

Volumn 66, Issue 6, 2006, Pages 3006-3014

  Ren, Juan ^a   Xiao, Yi Jin ^a,c   Singh, Lisam Shanjukumar ^a   Zhao, Xiaoxian ^a   Zhao, Zhenwen ^a   Feng, Li ^b   Rose, Tyler M ^b   Prestwich, Glenn D ^b   Xu, Yan ^a,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c XENOBIOTIC LABORATORIES INC   (United States)

^d INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (BROMOMETHYLENE) 3 [1 NAPHTHALENYL (2H TETRAHYDROPYRAN 2 ONE)] DERIVATIVE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; ASCITES; CANCER INVASION; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MESOTHELIUM CELL; OVARY CANCER; PRIORITY JOURNAL;

ARACHIDONIC ACIDS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; COLLAGEN TYPE I; CULTURE MEDIA, CONDITIONED; CYTOSOL; EPITHELIUM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; ISOENZYMES; LYSOPHOSPHOLIPIDS; NAPHTHALENES; OVARIAN NEOPLASMS; PERITONEAL CAVITY; PERITONEUM; PHOSPHODIESTERASE INHIBITORS; PHOSPHOLIPASES A; PROTO-ONCOGENE PROTEINS C-AKT; PYRONES;

EID: 33645525087     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1292     Document Type: Article

References (50)

1. Paget S. The distribution of secondary growth in cancer of the breast. Lancet 1889;1:571-3.
2. Pickel H, Lahousen M, Stettner H, Girardi F. The spread of ovarian cancer. Baillieres Clin Obstet Gynaecol 1989;3:3-12.
3. Gardner MJ, Jones LM, Catterall JB, Turner GA. Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Lett 1995;91:229-34.
4. Skubitz AP. Adhesion molecules. Cancer Treat Res 2002;107:305-29.
5. Offner FA, Obrist P, Stadimann S, et al. IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine 1995;7:542-7.
6. Xu Y, Fang XJ, Casey G, Mills GB. Lysophospholipids activate ovarian and breast cancer cells. Biochem J 1995;309:933-40.
7. Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1995;1:1223-32.
8. Xiao YJ, Schwartz B, Washington M, et al. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem 2001;290:302-13.
9. Shen Z, Belinson J, Morton RE, Xu Y. Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol Oncol 1998;71:364-8.
10. Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998;280:719-23.
11. Sutphen R, Xu Y, Wilbanks GD, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1185-91.
12. Lu J, Xiao YJ, Baudhuin LM, Hong G, Xu Y. Role of ether-linked lysophosphatidic acids in ovarian cancer cells. J Lipid Res 2002;43:463-76.
13. Sengupta S, Xiao YJ, Xu Y. A novel laminin-induced LPA autocrine loop in the migration of ovarian cancer cells. FASEB J 2003;17:1570-2.
14. Sengupta S, Wang Z, Tipps R, Xu Y. Biology of LPA in health and disease. Semin Cell Dev Biol 2004;15:503-12.
15. Schwartz BM, Hong G, Morrison BH, et al. Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol Oncol 2001;81:291-300.
16. Baudhuin LM, Cristina KL, Lu J, Xu Y. Akt activation induced by lysophosphatidic acid and sphingosine-1-phosphate requires both mitogen-activated protein kinase kinase and p38 mitogen-activated protein kinase and is cell-line specific. Mol Pharmacol 2002;62:660-71.
17. Xu Y, Xiao YJ, Zhu K, et al. Unfolding the pathophysiological role of bioactive lysophospholipids. Curr Drug Targets Immune Endocr Metabol Disord 2003;3:23-32.
18. Bian D, Su S, Mahanivong C, et al. Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. Cancer Res 2004;64:4209-17.
19. Xu J, Lai YJ, Lin WC, Lin FT. TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor. J Biol Chem 2004;279:10459-68.
20. Sawada K, Morishige K, Tahara M, et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res 2002;62:6015-20.
21. So J, Navari J, Wang FQ, Fishman DA. Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynecol Oncol 2004;95:314-22.
22. Symowicz J, Adley BP, Woo MM, Auersperg N, Hudson LG, Stack MS. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res 2005;65:2234-42.
23. So J, Wang FQ, Navari J, Schreher J, Fishman DA. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecol Oncol 2005;97:870-8.
24. 1. Cancer Res 2003;63:1706-11.
25. Van Leeuwen FN, Olivo C, Grivell S, Giepmans BN, Collard JG, Moolenaar WH. Rac activation by lysophosphatidic acid LPA1 receptors through the guanine nucleotide exchange factor Tiam1. J Biol Chem 2003; 278:400-6.
26. Fang X, Gaudette D, Furui T, et al. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann N Y Acad Sci 2000;905:188-208.
27. Shida D, Watanabe T, Aoki J, et al. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab Invest 2004;84:1352-62.
28. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003;3:582-91.
29. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 1993;291:677-80.
30. Pages C, Simon MF, Valet P, Saulnier-Blache JS. Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat 2001;64:1-10.
31. Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res 2000;6:2482-91.
32. Mills GB, Eder A, Fang X, et al. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res 2002;107:259-83.
33. Tokumura A, Miyake M, Nishioka Y, Yamano S, Aono T, Fukuzawa K. Production of lysophosphatidic acids by lysophospholipase D in human follicular fluids of in vitro fertilization patients. Biol Reprod 1999;61:195-9.
34. Aoki J, Taira A, Takanezawa Y, et ai. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem 2002;277:48737-44.
35. Moolenaar WH. Lysophospholipids in the limelight: autotaxin takes center stage. J Cell Biol 2002;158:197-9.
36. Umezu-Goto M, Kishi Y, Taira A, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002;158:227-33.
37. Tokumura A, Kanaya Y, Miyake M, Yamano S, Irahara M, Fukuzawa K. Increased production of bioactive lysophosphatidic acid by serum lysophospholipase D in human pregnancy. Biol Reprod 2002;67:1386-92.
38. Tokumura A, Majima E, Kariya Y, et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 2002;277-39436-42.
39. Lee TC, Zhang Y, Aston C, et al. Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res 1993;53:2858-64.
40. 2 assay for biochemical and cellular activity measurements. Chem Biol 2002;9:795-803.
41. Picq M, Huang Y, Lagarde M, Doutheau A, Nemoz G. Synthesis of photoreactive phosphatidic acid analogues displaying activatory properties on cyclic AMP-phosphodiesterases. Photoaffinity labeling of an isoform of phosphodiesterase. J Med Chem 2002;45:1678-85.
42. Keese CR, Bhawe K, Wegener J, Giaever I. Real-time impedance assay to follow the invasive activities of metastatic cells in culture. Biotechniques 2002;33:842-50.
43. Mohammed KA, Nasreen N, Ward MJ, Mubarak KK, Rodriguez-Panadero F, Antony VB. Mycobacterium-mediated chemokine expression in pleural mesothelial cells: role of C-C chemokines in tuberculous pleurisy. J Infect Dis 1998;178:1450-6.
44. Giaever I, Keese CR. Micromotion of mammalian cells measured electrically. Proc Natl Acad Sci U S A 1991;88:7896-900.
45. Casey RC, Oegema TR, Jr., Skubitz KM, Pambuccian SE, Grindle SM, Skubitz AP. Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells. Clin Exp Metastasis 2003;20: 143-52.
46. Tokumura A, Yamano S, Aono T, Fukuzawa K. Lysophosphatidic acids produced by lysophospholipase D in mammalian serum and body fluid. Ann N Y Acad Sci 2000;905:347-50.
47. 2 is coupled to hormonally regulated release of arachidonic acid. Proc Natl Acad Sci U S A 1992;89:6147-51.
48. Tigyi G, Parrill AL. Molecular mechanisms of lysophosphatidic acid action. Prog Lipid Res 2003;42:498-526.
49. Tokumura A, Miyake M, Yoshimoto O, Shimizu M, Fukuzawa K. Metal-ion stimulation and inhibition of lysophospholipase D which generates bioactive lysophosphatidic acid in rat plasma. Lipids 1998;33:1009-15.
50. Le Balle F, Simon MF, Meijer S, Fourcade O, Chap H. Membrane sidedness of biosynthetic pathways involved in the production of lysophosphatidic acid. Adv Enzyme Regul 1999;39:275-84.